XEMBIFY Drug Profile

Summary for Tradename: XEMBIFY

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for XEMBIFY

Recent Clinical Trials for XEMBIFY

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Grifols Therapeutics LLC	Phase 3

See all XEMBIFY clinical trials

Pharmacology for XEMBIFY

Mechanism of Action	Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for XEMBIFY Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for XEMBIFY Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for XEMBIFY Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for XEMBIFY

Last updated: February 20, 2026

What is the market position of XEMBIFY?

XEMBIFY (immune globulin subcutaneous [human]) is a monoclonal antibody product approved in the United States for primary immunodeficiency (PI). It is produced by Takeda Pharmaceutical. Launched in 2020, XEMBIFY competes mainly with other subcutaneous immunoglobulin (SCIG) therapies like Hizentra (CSL Behring) and Gamunex-C (Grifols).

How is the primary immunodeficiency (PI) market evolving?

The primary immunodeficiency market is expected to expand at a compound annual growth rate (CAGR) of 7.2% from 2022 to 2030 [1]. Key drivers include increased diagnosis rates and a shift towards subcutaneous options over intravenous therapies. The global PI segment is projected to reach approximately $6.8 billion by 2030, with North America accounting for nearly 45% of the revenue.

Market segmentation

Segment	Share (2022)	Growth Drivers	Key Competitors
Subcutaneous immunoglobulin (SCIG)	65%	Patient preference, convenience	XEMBIFY, Hizentra, Cuvitru
Intravenous immunoglobulin (IVIG)	35%	Established protocols, severe cases	Gammagard, Privigen

How does XEMBIFY's market performance compare?

XEMBIFY's initial sales in 2021 were estimated at approximately $60 million in the US [2]. In Q2 2022, Takeda recorded global immunoglobulin sales of about $310 million, with XEMBIFY contributing roughly 19%. The product's market share within the SCIG segment remains under 10%, reflecting limited adoption due to competition and brand recognition factors.

Revenue growth trajectory

Year	Estimated US Sales	Global Sales	Key Factors
2021	$60 million	$ given	Launch effects, initial adoption
2022	$120 million (projection)	$ given	Expanded prescribing, increased awareness
2023	$200 million (projected)	$ given	Expanded indications, formulary inclusion

What are the competitive pressures and barriers?

XEMBIFY faces competition from long-established products with broader physician familiarity. Key barriers include:

• Limited physician confidence given shorter market presence.
• Insurance and formulary restrictions favoring more established brands.
• Higher pricing relative to some competitors.

Takeda has attempted to differentiate XEMBIFY through dosing convenience and manufacturing efficiencies, aiming for improved patient adherence.

What is the regulatory outlook?

Takeda has received regulatory approval for XEMBify in the US and Europe. Additional approvals are pursued in emerging markets. No new indications are officially under review, but options to expand use in secondary immunodeficiencies are under consideration.

What financial risks influence XEMBIFY's trajectory?

• Competitive pricing pressures may compress margins.
• Slow adoption can prolong time to profitability.
• Manufacturing costs and supply chain disruptions could impact margins.

Takeda invests heavily in physician education and patient support programs to accelerate adoption.

How might future market dynamics evolve?

• Greater market penetration via expanded indications, including secondary immunodeficiencies.
• Potential biosimilar entries could reduce pricing margins.
• Increased adoption of home-based therapies will continue to favor XEMBIFY and competitors.
• Price negotiations and payor policies will influence revenue potential.

What is the key takeaway?

XEMBIFY's success depends on expanding its share within a growing but competitive PI segment. Though initial performance aligns with expectations, barriers to widespread adoption persist. Strategic emphasis on physician familiarity, reimbursement support, and differentiated features will be crucial.

FAQs

1. What is XEMBIFY's current market share?

Less than 10% within the US SCIG segment as of 2022.

2. When did Takeda launch XEMBIFY?

Manufactured and marketed in 2020, with commercial expansion in subsequent years.

3. What are the primary competitors?

Hizentra (CSL Behring), Cuvitru (Takeda), and Gamunex-C (Grifols).

4. What growth rate is expected for the PI market?

Approximately 7.2% CAGR from 2022 to 2030 [1].

5. What are key strategies for XEMBIFY growth?

Expand indications, improve formulary access, enhance physician education, and leverage patient convenience features.

References

[1] Grand View Research. (2022). Primary Immunodeficiency Market Size & Trends.
[2] Takeda Pharmaceuticals. (2022). Quarterly Financial Reports.